Phase 1, Multiple Dose Study of MPC-6827 in Subjects With Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

April 30, 2007

Study Completion Date

February 29, 2008

Conditions

Refractory Solid Tumors

Interventions

DRUG

MPC-6827

2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle

Trial Locations (2)

University of Texas MD Anderson Cancer Center, Houston

Huntsman Cancer Institute at the University of Utah, Salt Lake City